Please login to the form below
anxiety
This page shows the latest anxiety news and features for those working in and with pharma, biotech and healthcare.
Prescription drug dependence 'linked to deprivation', says PHE
This included benzodiazepines for anxiety and insomnia, z-drugs for insomnia, gapapentinoids for neuropathic pain, opioid pain medications for chronic non-cancer pain and antidepressants.
Latest news
-
Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment
Pear Therapeutics says the study also showed improvements in anxiety symptoms (as measured by the General Anxiety Disorder 7-item (GAD-7) scale), with a treatment arm mean of 3.16
-
Otsuka’s Alzheimer’s agitation drug hits the mark
antipsychotic drugs – which have been linked to a higher risk of death in dementia – as well as antidepressants and anxiety medications.
-
Hidden health system costs: false positives and negatives
And maybe I suffer from some stress and anxiety. Or a false negative?
-
Sage’s postpartum depression treatment Zulresso gains US approval
Unlike conventional antidepressants, which can take weeks to kick in, the single infusion starts working within 2-3 days of dosing and can lift women quickly out of the sadness, anxiety,
-
Sage raises $575m ahead of FDA review date for Zulresso
Unlike conventional antidepressants, which can take weeks to kick in, Zulresso starts working within two to three days of dosing and can lift women quickly out of the sadness, anxiety, irritability,
More from news
Approximately 1 fully matching, plus 146 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
However, the HTA acknowledges the limitations of the index, noting that “the DLQI has limited validity in some people, and may miss anxiety and depression.”.
-
Changing healthcare communications
Replacing anxiety with confidence, mediocrity with purpose. By David Hunt and Lou Shipley. ... But only if we replace anxiety with confidence, mediocrity with purpose, and attract the brightest, smartest and most creative minds to join our cause.
-
Drug launches to watch in 2019
There were also significant improvements for AbbVie’s drug over Humira on quality of life measures and over Stelara on anxiety and depression, and risankizumab did better than both comparator drugs
-
AstraZeneca’s oncology renaissance
Galbraith is concerned about the rise in reported anxiety and mental health problems in young people, with young women most vulnerable.
-
The Patient Safety Challenge
There were anxieties about how reporting could affect their reputations and career prospects.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Dr Niall Murphy and Pierre Schwich join Pharnext
Prior to this, Dr Murphy served as a unit leader for a team of scientists collaborating on research in the areas of addition biology, Alzheimer's disease, anxiety, depression and neurotoxicity
-
Turing names Eliseo Salinas as head of R&D
Salinas has played a leading role in numerous programmes for a range of diseases and disorders, with specific focus on central nervous systems (CNS) condition such as depression and anxiety, schizophrenia,
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The era of digital wellbeing
However, it’s rise in popularity has resulted in both positive and negative outcomes, with the latter increasing bullying, depression and anxiety the world over. ... depression, anxiety, aggression, and antisocial behaviour.
-
PHARMA CONTENT MARKETING COMES OF AGE - ‘15 MINUTES OF FURY’ A MENTAL HEALTH & SOCIAL MEDIA FILM
A short film which aims to reduce stigma around mental health conversations in underserved grassroots communities in the UK. London, October 2019 - A private screening will be held on October 9th, in Central London. The film will be released on
-
The benefits of uniting in a divergent environment
Nominated tonight is the already award-winning Genetic Links to Anxiety and Depression (GLAD) study campaign for King’s College London, which combined traditional media formats, broadcast, social media and digital
-
When it’s OK to not be OK: Bedrock breaks down mental health stigma
Over the course of the session, the Bedrock team opened up about the causes of stress and anxiety in our personal and professional lives, discussing the things that challenge us and ... It’s important that we all help push to break down the stigma of
-
What is changing in mental health and dementia care?
year by 2020/21, with an increasing focus on those with long-term conditions who also require treatment for mild to moderate depression and anxiety.
More from PMHub
Approximately 1 fully matching, plus 28 partially matching documents found.
Featured jobs
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Scientific Director - Medical Communications Agency - New York
-
Excellent Remuneration Package
- Senior / Principal Medical Writer – Medical Education - UK &...
-
Excellent Salary and Benefits on offer
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Scientific Director - Medical Education - Cheshire & London ...
-
Excellent Remuneration Package
-
Account Director, Medical Education
-
Salary TBC
- Graduate / Entry Level Opportunities – Medical Communications – ...
-
Highly Competitive Remuneration Package
- Senior Medical Writer – Leading Medical Communications Agency – ...
-
Highly Competitive Remuneration Package
-
Senior Medical Writer
-
Salary TBC
- Experienced / Senior Medical Writer - MedComms - Cardiff - Wales
-
Excellent Salary and Benefits on offer
Subscribe to our email news alerts
- Moving annual total (MAT)
- Novartis highlights emerging assets and late-stage pipeline at R&D day
- Seattle Genetics moves to dismiss ADC lawsuit with Daiichi Sankyo
- PMEA 2019 Winners Gallery - PMEA
- Creativity in storytelling: why pharma must invest more in creativity
- UPDATED: BMS completes Celgene merger after FTC okay
- Five key trends in precision and personalised healthcare
- Biogen defends aducanumab filing plan amid scepticism
- UCB’s bimekizumab beats AbbVie’s Humira in phase 3 trial
- Novartis strengthens case for its combination asthma drug
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Sage slides off a MOUNTAIN as depression drug flunks trial
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Five key trends in precision and personalised healthcare
- Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
- OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
- Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
- Language barriers: Obesity has become a loaded word
- ...
Quick links
Infographics
